Comparative evaluation of costs and healthcare resource utilization of oral selexipag versus inhaled treprostinil or oral treprostinil in patients with pulmonary arterial hypertension.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of medical economics"
DOI: 10.1080/13696998.2023.2204769
Abstract: BACKGROUND Pulmonary arterial hypertension (PAH), a rare vasculopathy progressively leading to right heart failure and death, is associated with considerable economic burden. Oral prostacyclin pathway agents (PPAs) like selexipag and treprostinil address an underlying PAH… read more here.
Keywords: oral treprostinil; treprostinil oral; oral selexipag; inhaled treprostinil ... See more keywords